| Biomarker ID | 666 |
| PMID | 21629784 |
| Year | 2011 |
| Biomarker | PSA+ Grade + Stage +MKI67 (Ki-67) + TOP2A (DNA topoisomerase II, alpha) + E2F1 (E2F transcription factor 1) |
| Biomarker Basis | Expression Based |
| Biomolecule | Genes |
| Source | Tissue |
| Subjects | Humans |
| Regulation | TOP2A, E2F1: Increased expression with earlier Biochemical Recurrence, |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include(MKI67) :-ID regulation of gene expression,Prostate cancer, Androgen receptor proteolysis and transcription regulation, Androgen receptor signaling, proteolysis, and transcription regulation, Insulin-like growth factor (IGF) activity regulation by insulin-like growth factor binding proteins (IGFBPs) Pathways Include(MKI67):- RANKL regulation of apoptosis and immune response Pathways Include(TOP2A) :-Apoptotic DNA fragmentation and tissue homeostasis,G0 and early G1 pathway,Delta Np63 pathway,Mitotic G1-G1/S phases,Interleukin-4 regulation of apoptosis Pathways Iclude(E2F1):- Effect of METS on macrophage differentiation, Activation of BH3-only proteins, Interleukin-2/PI3K pathway, Apoptosis intrinsic pathway, G0 and early G1 pathway |
| Experiment | PSA Reccurence Vs No Recurrence for 8 years |
| Type of Biomarker | Prognostic |
| Cohort | Total of 139 patients who had prostate cancer were included in the study with 20 having Gleason Score 6, 117 having Gleason Score 7 and 2 having GS >=8. |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.816 |
| Accuracy | NA |
| Level Of Significance | p=0.005 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | KLK3, MKI67, TOP2A, E2F1 |